UP!

CBPO $107.45   View long term graphs

China Biologic Products, Inc.
Type
Public
Traded as NASDAQ: CBPO
Industry Biotechnology
Headquarters Beijing, China
Website www.chinabiologic.com

China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is the only blood plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province in China with a population of 93 million. The company is engaged in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Plasma-based human albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment.

News

China Biologic Products Holdings, Inc. 1% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-10 Future report Set alerts
Q3 2020 2020-11-11 Future report Set alerts
Q2 2020 2020-08-17 1.11 0.91
Q1 2020 2020-05-20 1.56 1.36
Q4 2019 2020-03-12 0.53 0.32
Q3 2019 2019-11-13 1.40 1.21
Q2 2019 2019-08-05 1.24 1.06
Q1 2019 2019-05-10 1.11 0.94
Q4 2018 2019-03-06 0.76 0.87
Q3 2018 2018-11-01 0.96 0.94

Ratings

2016-07-05 Upgrade Credit Suisse Group AG Neutral to Outperform
2016-06-04 Reiterated Rating Jefferies Group Buy
2016-03-01 Downgrade Credit Suisse Outperform to Neutral $129.00
2016-03-01 Downgrade Credit Suisse Group AG Outperform to Neutral $129.00
2016-02-29 Lower Price Target Jefferies Group Buy $138.00 to $136.00
2016-01-07 Boost Price Target Deutsche Bank Buy $149.00 to $162.00
2016-01-07 Boost Price Target Deutsche Bank AG Buy $149.00 to $162.00
2015-10-08 Initiated Coverage Credit Suisse Outperform
2015-09-04 Reiterated Rating Jefferies Group Buy $146.00
2015-07-13 Initiated Coverage Deutsche Bank Buy $149.00
2015-07-09 Initiated Coverage Bank of America Buy $135.00
2015-07-09 Initiated Coverage Bank of America Corp. Buy $135.00
2015-06-12 Reiterated Rating Jefferies Group Buy $115.00 to $122.00
2014-11-06 Reiterated Rating Jefferies Group Buy $57.00 to $76.00
2014-09-03 Reiterated Rating Aegis Buy $55.00 to $59.00
2014-07-24 Reiterated Rating Jefferies Group Buy $52.00 to $57.00
2014-07-08 Reiterated Aegis Capital Buy $50 to $55
2014-07-08 Boost Price Target Aegis Buy $50.00 to $55.00
2014-05-22 Initiated Coverage Jefferies Group Buy $52.00
2014-03-17 Upgrade Aegis Buy
2014-03-14 Initiated Oppenheimer Outperform $46
2014-03-13 Initiated Coverage Oppenheimer Outperform $46.00
2013-11-06 Downgrade Aegis Capital Buy to Hold
2013-11-06 Downgrade
2013-11-06 Downgrade Aegis Buy to Hold
2013-03-14 Reiterated Aegis Capital Buy $22 to $28
2010-05-13 Reiterated Brean Murray Buy $19 to $20
2010-03-26 Reiterated Brean Murray Buy $15 to $19
2016-07-05 Upgrade Credit Suisse Group AG Neutral to Outperform
2016-06-04 Reiterated Rating Jefferies Group Buy
2016-03-01 Downgrade Credit Suisse Outperform to Neutral $129.00
2016-03-01 Downgrade Credit Suisse Group AG Outperform to Neutral $129.00
2016-02-29 Lower Price Target Jefferies Group Buy $138.00 to $136.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments